General Information of Drug (ID: DMN4I7P)

Drug Name
GSK3901961 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMN4I7P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CDX-1401 DMCGNJ6 Ovarian cancer 2C73 Phase 2 [2]
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [3]
Anti-NY-ESO-1 CAR-T cells DM26VCZ Esophageal cancer 2B70 Phase 1/2 [4]
NY-ESO-1 vaccine DM0EKUQ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
GSK-2241658A DM5VS7B Melanoma 2C30 Phase 1 [6]
GSK3845097 DM1UQ4Y Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Melanoma vaccine (ALVAC) DM3HIQY Melanoma 2C30 Discontinued in Phase 2 [7]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cancer/testis antigen 1 (NY-ESO-1) TTE5ITK CTG1B_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of GlaxoSmithKline.
2 National Cancer Institute Drug Dictionary (drug id 651880).
3 National Cancer Institute Drug Dictionary (drug id 648549).
4 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
5 Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
6 ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
7 Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.